30 closest matches · ranked by relevance
Hepatitis A · Measles · Mumps
Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants
Varicella · Chickenpox Vaccines
Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001
Measles; Mumps; Rubella; Chickenpox · Measles
Primary: GMC of Anti-measles Antibodies at Day 43 — 801; 788; 728; 682 mIU/mL
Hepatitis A Virus
Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Varicella Antibody Titer ≥5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL for Subjects Initially…
Measles · Mumps · Rubella
Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL — 97.3; 93.0 Percentage of participants — p=<0.001
Measles · Varicella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies Greater Than or Equal to (≥) the Cut-off Value. — 312; 157; 279; 142 Participants
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions — 7 participants
Measles; Mumps; Rubella · Measles-Mumps-Rubella Vaccine
Primary: Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination — 47; 17; 205; 95 Participants
Varicella · Rubella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies — 149; 153; 72; 149 Participants
Rubella · Mumps · Measles
Primary: Anti-measles Virus Antibody Concentrations. — 1795.6; 1783.3 mIU/mL
Japanese Encephalitis · Measles · Mumps
Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…
Hepatitis A
Primary: Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. — 1390.4; 1895.2 mIU/mL
Rubella · Mumps · Measles
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value. — 245; 236; 236; 248 Subjects
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions (ADRs) — 2 Participants
Measles-Mumps-Rubella
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value — 697; 249; 736; 281 Participants
Measles · Varicella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Zoster Virus (VZV) Antibodies Above the Cut-off Values — 294; 155; 262; 145 Participants…
Tetanus · Acellular Pertussis · Diphtheria
Primary: Number of Subjects With Booster Responses to Diphteria and Tetanus — 209; 207; 208; 203 Participants
Encephalitis, Japanese · Measles · Mumps
Primary: Percentage of Participants With Measles Seropositivity 56 Days Post-vaccination — 98.1; 98.0 percentage of participants
Rubella · Varicella · Measles
Primary: Number of Seroconverted Subjects for Measles, Mumps, Rubella, and Varicella Virus — 305; 162; 292; 151 Participants
Measles · Mumps · Rubella
Primary: Number of Participants With Varicella Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥ 5 gpELISA Units — 198; 299; 253; 303 Participants
Measles · Mumps · Rubella
Primary: Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by Enzyme-linked Immunosorbent Assay [ELISA]) — 90.9; 94.3…
Varicella
Primary: Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process). — 96.3 Percent of participants
Meningococcal Meningitis · Measles · Mumps
Primary: Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only) — 98; 98; 95; 95 Percentage of Participants
Varicella · Rubella · Mumps
Primary: Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV) — 355; 440; 301 subjects
Measles Antibody Seroconversion · Rubella Antibody Seroconversion · Rotavirus Geometric Mean Titer (GMT)
Primary: Percentage/Number of Subjects With Seroprotection for Measles Virus Serum Neutralization Antibodies — 171; 173; 56; 60 Participants
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL — 726; 718; 736; 772…
Measles · Rubella · Rubella Syndrome, Congenital
Primary: Percent of Infants Who Were Seropositive After Immunization at 6 Months (Assessed at 9-month Visit) — 94; 94 percentage of infants
Rubella · Measles · Mumps
Primary: Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value — 98.2; 98.9; 98.1; 98.1 Percentage of subjects
Varicella · Measles · Mumps
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella — 97.4; 96.3; 96.7; 98.6 Percentage of Participants